Last $19.15 USD
Change Today +0.57 / 3.07%
Volume 1.4M
RGLS On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 8:10 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

regulus therapeutics inc (RGLS) Snapshot

Open
$18.45
Previous Close
$18.58
Day High
$19.68
Day Low
$18.39
52 Week High
11/10/14 - $25.60
52 Week Low
05/9/14 - $5.40
Market Cap
930.8M
Average Volume 10 Days
742.3K
EPS TTM
$-0.92
Shares Outstanding
48.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for REGULUS THERAPEUTICS INC (RGLS)

regulus therapeutics inc (RGLS) Related Businessweek News

View More BusinessWeek News

regulus therapeutics inc (RGLS) Details

Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs for the treatment of various diseases in the United States. The company uses its microRNA product platform to develop anti-miRs, which is chemically modified and single-stranded oligonucleotide. Its clinical candidate products include RG-101, which is a GalNAc-conjugated anti-miR that targets microRNA-122 for the treatment of patients with chronic hepatitis C virus infection. The company has strategic collaboration with Biogen Idec MA Inc. for the evaluation of the use of microRNA signatures as a biomarker for human patients with multiple sclerosis; AstraZeneca AB to discover and develop microRNA therapeutics for cardiovascular diseases, metabolic diseases, and oncology; and GlaxoSmithKline plc to discover and develop microRNA therapeutics for immuno-inflammatory diseases. It also has strategic collaboration with Sanofi for the discovery and development of microRNA therapeutics comprising miR-21 pre-clinical fibrosis program for the treatment of alport syndrome and preclinical program for oncology indications; and preclinical programs targeting miR-221/222 for oncology indications. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.

81 Employees
Last Reported Date: 08/7/14
Founded in 2007

regulus therapeutics inc (RGLS) Top Compensated Officers

Chief Executive Officer, President, Principal...
Total Annual Compensation: $600.0K
Chief Scientific Officer
Total Annual Compensation: $350.0K
Compensation as of Fiscal Year 2013.

regulus therapeutics inc (RGLS) Key Developments

Regulus Therapeutics Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015

Regulus Therapeutics Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 . Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.

Regulus Therapeutics Inc. Presents at Boston Biotech Conferences LLC's The East Meets West CEO conference, Jan-10-2015 through Jan-11-2015

Regulus Therapeutics Inc. Presents at Boston Biotech Conferences LLC's The East Meets West CEO conference, Jan-10-2015 through Jan-11-2015. Venue: Four Seasons Hotel, 757 Market St, San Francisco, CA 94103. Presentation Date & Speakers: Jan-10-2015, Kleanthis G. Xanthopoulos, Chief Executive Officer, President, Principal Financial & Accounting Officer and Director.

Regulus Therapeutics Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-03-2014 02:00 PM

Regulus Therapeutics Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-03-2014 02:00 PM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: Kleanthis G. Xanthopoulos, Chief Executive Officer, President, Principal Financial & Accounting Officer and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RGLS:US $19.15 USD +0.57

RGLS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Benitec Biopharma Ltd A$0.80 AUD +0.025
Galena Biopharma Inc $1.63 USD 0.00
Prosensa Holding NV $18.74 USD +0.06
Silence Therapeutics PLC 222.00 GBp 0.00
Tekmira Pharmaceuticals Corp C$32.68 CAD -0.22
View Industry Companies
 

Industry Analysis

RGLS

Industry Average

Valuation RGLS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 59.6x
Price/Book 10.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 58.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REGULUS THERAPEUTICS INC, please visit www.regulusrx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.